Based on the collected antibiotic concentration data and individual patient's clinical information, a pharmacokinetic analysis report that can be applied for dose adjustment of the individual patient is provided. The pharmacokinetic/pharmacodynamic index using the minimum inhibition concentration (MIC) of the antibiotic obtained from the patient's clinical isolate is also explored. Utilizing these, we intend to establish a population pharmacokinetic model of antibiotics prescribed in treating Tuberculosis and Nontuberculous mycobacteria (NTM). The developed population pharmacokinetic model can be applied for therapeutic drug monitoring (TDM) based on dose adjustment through the obtained pharmacokinetic parameters.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The maximum plasma concentration (Cmax)
Timeframe: Around 2 weeks or later after the first administration of antibiotics
Area under the plasma concentration versus time curve (AUC)
Timeframe: Around 2 weeks or later after the first administration of antibiotics
Development of population pharmacokinetic (PK) model of antibiotics
Timeframe: Through study completion, an average 3 years
AUC/MIC
Timeframe: Through study completion, an average 3 years
Cmax/MIC
Timeframe: Through study completion, an average 3 years
Time above MIC (T > MIC)
Timeframe: Through study completion, an average 3 years